U.S. Companion Animal Diagnostics Market Size, Share, Competitive Landscape and Trend Analysis Report, by Technology, by Application, by Animal Type, by End User : Opportunity Analysis and Industry Forecast, 2021-2031

U.S. companion animal diagnostics market Research 2032:

The U.S. companion animal diagnostics market size was valued at $1,491.11 Million in 2022, and is projected to reach $3,271.71 Million by 2032, registering a CAGR of 8.2% from 2023 to 2032.

Companion animals, often referred to as pets, are domesticated animals that provide companionship, and emotional support to their human caregivers. Companion animals typically live with humans in their homes and become integral members of the family. Common examples of companion animals include dogs and cats. Some other companion animals include horses, small furries, ornamental fish, and caged birds. Companion animal diagnostics is a diagnostic method that is used to identify a chronic disease in companion animals. For the detection of diseases, several diagnostics methods are used such as molecular diagnostic, immunodiagnostic, clinical biochemistry, uranalysis, and others.

Market dynamics

The rise in prevalence of chronic diseases in companion animals, increase in pet ownership in the U.S., surge in awareness about the health of companion animals, and high adoption of health insurance for pets by their owners are expected to drive the growth of the market.

The rise in prevalence of chronic diseases among companion animals has emerged as a significant driving force behind the growth of the U.S. companion animal diagnostic market. There has been a concerning uptick in the occurrence of chronic conditions such as diabetes, obesity, cardiovascular diseases, feline immunodeficiency virus, and cancer in pets in the U.S. According to IDEXX Laboratories, a global biotechnology company, it was estimated that approximately 10% of all dogs in the U.S. have heart disease. As the incidence of cardiovascular diseases in pets increases, there is a growing need for advanced diagnostic tools and tests to identify, monitor, and manage these conditions in pets. Additionally, blood tests for cardiac biomarkers and genetic testing for predisposition to heart diseases are becoming more common. The market for these diagnostic services and tools has expanded due to the need for accurate and timely diagnosis of cardiovascular conditions in pets.

In addition, according to National Library of Medicine, in 2021 it was estimated that in the U.S, prevalence of feline immunodeficiency virus ranges from 3% in the overall population to 18% in sick cats.  The rising prevalence of feline immunodeficiency virus has led to a greater emphasis on diagnostic testing, including serological tests to detect feline immunodeficiency virus antibodies, viral load measurement, and molecular tests for viral DNA/RNA. Early detection and diagnosis of feline immunodeficiency virus are crucial for timely intervention and management, which has driven the demand for feline immunodeficiency virus diagnostic tests in veterinary practices and clinics. Thus, the surge in prevalence of chronic diseases in companion animals has emerged as a catalyst propelling the growth of the U.S. companion animal diagnostic market.

Furthermore, the U.S. has witnessed a remarkable surge in pet ownership, which has emerged as a significant catalyst propelling the growth of the U.S. companion animal diagnostic market. The surge in pet ownership is attributed to the fact that individuals and families recognize the manifold benefits of having pets, ranging from companionship and emotional support to increased physical activity and stress reduction. According to National Pet Owners Survey, in 2022, 90.5 million families in the U.S. owned a pet. Pets are no longer seen merely as domesticated animals as they are now regarded as beloved family members and sources of emotional support. This shift in perception has led to a heightened sense of responsibility among pet owners to ensure the well-being of their animal companions.

The rise in pet ownership has not only stimulated the demand for routine check-ups and preventative care but has also led to an increased willingness to explore advanced diagnostic options for more complex medical conditions. Thus, the surge in pet ownership in the U.S. has emerged as a pivotal force driving the growth and diversification of the companion animal diagnostic market.

Moreover, the remarkable surge in the adoption of health insurance for pets in the U.S. has emerged as major driver for the market. The increasing awareness of the potential healthcare costs associated with veterinary care and treatments has driven a substantial number of pet owners to invest in comprehensive health insurance coverage for their animals. According to American Pet Products Association, in 2021, it was reported that the total expenditure on pet health care increased from $103.6 billion in 2020 to $109.6 billion in 2021 in the U.S. Pet owners are now more attuned to the intricate medical needs of their beloved companions, recognizing the importance of timely and accurate diagnostic services to ensure early detection and effective management of potential health issues. As a result, there has been a surge in demand for advanced diagnostic tools and services, ranging from routine check-ups to more sophisticated imaging techniques and laboratory tests. This, in turn, has enabled pet owners to pursue more proactive and preventive healthcare measures for their animal companions, translating into improved overall health outcomes and extended lifespans for pets. Thus, the escalating adoption of health insurance for pets has emerged as a driving force behind the robust expansion of the U.S. companion animal diagnostic market

However, lack of skilled professionals is expected to restrain the growth of the U.S. companion animal diagnostics market. Moreover, growth in demand for rapid tests and portable instruments for PoC diagnostic services and surge in awareness related to animal healthcare are anticipated to present significant growth opportunities.

The outbreak of the COVID-19 pandemic has had a significant impact on various industries worldwide, and the U.S. companion animal diagnostics market is no exception. With restrictions imposed during lockdowns and social distancing measures, there was a notable decline in routine veterinary visits, which led to a temporary slowdown in the demand for companion animal diagnostics services. Many pet owners were hesitant to take their pets to veterinary clinics unless for urgent care, resulting in decreased testing volumes for non-essential procedures. Supply chain disruptions and shortages of critical diagnostic resources posed challenges, affecting the availability of certain tests and equipment. However, the pandemic also spurred some significant shifts in the market. As people spent more time at home, there was a noticeable increase in pet adoption rates, resulting in a larger pet population. In post pandemic phase, the market is expected to recover significantly owing to the rise in awareness about animal healthcare.

Segmental Overview

 The U.S. companion animal diagnostics market is segmented on the basis of technology, application, animal type, and end user.  Depending on technology, the market is segmented into clinical biochemistry, immunodiagnostics, hematology, molecular diagnostics, urinalysis, and others. On the basis of application, the market is segmented into clinical pathology, bacteriology, virology, parasitology, and others. As per animal type, it is divided into dogs, cats, and others. By end user, it is segmented into diagnostics labs, point of care and in-house testing, research institutes and universities, and veterinary hospitals and clinics.

By Technology:

The U.S. companion animal diagnostics market is categorized into clinical biochemistry, immunodiagnostics, hematology, molecular diagnostics, urinalysis, and others. The clinical biochemistry segment dominated the market in 2022 and is expected to remain dominant during the forecast period. This is attributed to the fact that clinical biochemistry technology is used to diagnose wide range of diseases in companion animals.

By Application:

By applications, the market is divided into clinical pathology, bacteriology, virology, parasitology, and others. The clinical pathology segment dominated the market in 2022 and is expected to remain dominant during the forecast period, owing to rise in incidence of chronic diseases such as cancer gastrointestinal parasites and diabetes.

By Animal Type:

By animal type, the market is divided into dogs, cats and others. The dogs segment dominated the market in 2022 and is expected to remain dominant during the forecast period. This is attributed to the higher adoption rate of dogs as companion animals.

By End User:

By end user, the market is divided into diagnostics labs, point of care and in-house testing, research institutes and universities, and veterinary hospitals and clinics. The diagnostics labs segment dominated the market in 2022. This is attributed to the availability of a wide range of diagnostic equipment in diagnostic labs for veterinary testing.

Competition Analysis

Competitive analysis and profiles of the major players in the U.S. companion animal diagnostics market, such as Alfa Wassermann, Inc., AnimalBiome, Biomerieux SA, BioNote Inc., Bio-Rad Laboratories, Creative Diagnostics, Fujifilm Holdings Corporation, Heska Corporation, Idexx Laboratories Inc., Indical Bioscience GmbH, Innovative Diagnostics, Neogen Corporation, Randox Laboratories Ltd., Shenzhen Mindray Animal Medical Technology Co. Ltd., Thermo Fisher Scientific, Virbac, and Zoetis Inc. are provided in the report. Major players have adopted product launch, product development, and partnership as key developmental strategies to improve the product portfolio and gain strong foothold in the market.

Recent product launch in the U.S. companion animal diagnostics market

In November 2022, Bionote U.S., a biotechnology company, has added in-clinic Troponin I (TnI) in-vitro diagnostic test kits for the quantitative measurement of canine and feline Troponin I to its Vcheck line of biomarker tests and immunoassay analyzers. This product addition widens Vcheck’s exclusive cardiac menu, which also includes the NT-proBNP tests for canines and felines. The addition makes Bionote the only manufacturer in the veterinary marketplace to offer fully-quantitative Troponin I for both species.

In July 2020, Bionote U.S., a biotechnology company, has added the first and only in-clinic, in vitro diagnostic test kit for the quantitative measurement of NT-proBNP concentration in canine serum to its Vcheck product line.

Recent partnership in the U.S. companion animal diagnostic market

In July 2022, Bionote U.S., a biotechnology company, announced a new partnership with PSIvet, which is the nation's largest veterinary group purchasing organization. The partnership will make Bionote U.S. Vcheck line of analyzers and tests even more affordable to PSIvet’s 5,000-plus veterinary practices.

Recent product development in the U.S. companion animal diagnostics market

In April 2022, Zoetis Inc, a global animal health company, added artificial intelligence (AI) blood smear and fecal testing to its existing platform, VETSCAN Imagyst.

  U.S. Companion Animal Diagnostics Market Report Highlights